TABLE 1.
The distribution of sample size by site and age group for assessment of immune response as part of Vi capsular polysaccharide vaccine effectiveness trials in Karachi and Kolkata
| Blood sample collection no. and time period | Age group (yr) | Sample sizes (n [%]) in: |
Total (n [%]) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Karachi |
Kolkata |
|||||||||
| Vi | HepAa | Total | Vi | HepA | Total | Vi | HepA | Total | ||
| 1, day 0/prevaccination | 2–5 | 57 (46.7) | 47 (40.9) | 104 (43.9) | 3 (9.7) | 5 (15.6) | 8 (12.7) | 60 (39.2) | 52 (35.4) | 112 (37.3) |
| 5–16 | 65 (53.3) | 68 (59.1) | 133 (56.1) | 28 (90.3) | 27 (84.4) | 55 (87.3) | 93 (60.8) | 95 (64.6) | 188 (62.7) | |
| 2, 6 wk after vaccination | 2–5 | 40 (43.5) | 36 (39.6) | 76 (41.5) | 2 (6.5) | 3 (10.3) | 5 (8.3) | 42 (34.2) | 39 (32.5) | 81 (33.3) |
| 5–16 | 52 (56.5) | 55 (60.4) | 107 (58.5) | 29 (93.6) | 26 (89.7) | 55 (91.7) | 81 (65.9) | 81 (67.5) | 162 (66.7) | |
| 3, 2 yr after vaccination | 2–5 | 20 (43.5) | 17 (37.8) | 37 (40.7) | 1 (4.0) | 2 (8.7) | 3 (6.3) | 21 (29.6) | 19 (27.9) | 40 (28.8) |
| 5–16 | 26 (56.5) | 28 (62.2) | 54 (59.3) | 24 (96.0) | 21 (91.3) | 45 (93.8) | 50 (70.4) | 49 (72.1) | 99 (71.2) | |
| All three samples | 2–5 | 19 (42.2) | 14 (34.2) | 33 (38.4) | 1 (4.2) | 2 (8.7) | 3 (6.4) | 20 (29.0) | 16 (25.0) | 36 (27.1) |
| 5–16 | 26 (57.8) | 27 (65.9) | 53 (61.6) | 23 (95.8) | 21 (91.3) | 44 (93.6) | 49 (71.0) | 48 (75.0) | 97 (72.9) | |
a
HepA, hepatitis A vaccine.